BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with ...
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding ...
Tiziana Life Sciences is following biotech’s third-quarter cull trend, though it’s attempting to do so more covertly, putting several of its pipeline programs on the shelf in a “near-term focus” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results